Oncodesign has signed an agreement with Eisai. Oncodesign reported that it will conduct in vivo pharmacology studies and Eisai will provide gene expression profiling analysis using Oncodesign's patient-derived xenograft models (PDX) to investigate ... Individual.com, 2 days ago
Oncodesign has entered into a services agreement with Eisai to develop a new personalized medicine program in earlier line metastatic breast cancer treatment - Street Sweeper, 4 days ago
Oncodesign SA Has Entered Into A Services Agreement With Eisai Inc. To Develop A New Personalized Medicine Program In Earlier Line Metastatic Breast Cancer Treatment - BioSpace, 3 days ago
More from: Reuters UK, Stock Nod...and 37 other sources
Eisai Co., Ltd., has announced that its Brazilian subsidiary Eisai Laboratorios Ltda. has launched the anticancer agent Halaven, also known as eribulin mesylate. This marks the Eisai Group's first product to be marketed by Eisai in Latin America. ...Individual.com, 1 week ago Eisai launches antiepileptic drug in Hong Kong Individual.com, 2 weeks ago
Eisai Co., Ltd., a Japanese pharmaceutical company, has announced new production facility in Suzhou, Jiangsu, China. Historically, Eisai has operated its Suzhou Plant for the manufacturing and packaging of solid preparation products for the local ...Individual.com, 1 week ago Eisai Deepens Its Presence In China Asian Scientist, 1 week ago Eisai gets direct presence in China Bio Spectrum Asia, 2 weeks ago
Halaven (eribulin) manufactured by Japanese drug major Eisai (TYO: 4523) is now available in Russia. It is indicated to treat patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen ...Pharma Letter, 3 days ago New Data Show That 30% of People Were Free of Primary Generalised Tonic Clonic Seizures When Using Adjunctive Fycompa(R) (perampanel) Individual.com, 2 weeks ago Eisai's Halaven with Capecitae Provides Clinical Benefit for Women with Metastatic Breast Cancer FirstWord Pharma, 1 week ago NEWS FROM THE AMERICAN EPILEPSY SOCIETY ANNUAL MEETING: Perampanel Found to Reduce Tonic Clonic Seizures Neurology Today, 3 days ago
More from: ADVFN UK, Biotechgate...and 9 other sources
Eisai Listed for 13th Consecutive Year in FTSE4GOOD Index Series, an Index for Socially Responsible Investment
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has been listed for the 13th consecutive year since 2002 in the FTSE4Good Index Series, a global index for socially responsible investment. The FTSE4Good ...Stockwatch, 4 days ago EISAI : Listed for 13th consecutive year in ftse4good index series, an index for socially responsible investment 4 Traders, 3 days ago Eisai's innovatives Individualimport-Programm für den ersten Vertreter einer neuen Wirkstoffklasse Fycompa® (Perampanel) wird trotz verheerender… Gnom.es, 1 week ago Eisai Demonstrates Efficacy of Investigational Dual Orexin Receptor Antagonist E2006 in Sleep Initiation and Maintenance Data from Phase II Clinical Trial for Insomnia Digital Journal, 1 week ago
By Suzanne Hodsden , contributing writer Japan-based Eisai has opened two new manufacturing facilities, one in Suzhou , Jiangsu China and the other in the U.K. Investment in the new space is expected to improve Eisai's supply chain and ...Bioresearch Online, 2 weeks ago Eisai opens new plants targeting Asia and Europe FiercePharmaManufacturing, 2 weeks ago
Eisai Inc. Presents New Data On Perampanel And Rufinamide At The 68th Annual American Epilepsy Society Meeting
WOODCLIFF LAKE, N.J. , Dec. 5, 2014 /PRNewswire/ --Eisai Inc. announced today that 16 abstracts highlighting new data on perampanel and rufinamide will be presented at the 68 th Annual American Epilepsy Society (AES) meeting, taking place in ...BioSpace, 1 week ago Eisai Presents New Data on Perampanel and Rufinamide at the 68th Annual American Epilepsy Society Meeting Crawford Financial Planning, 2 weeks ago Eisai Inc. Release: New Research On Eribulin Mesylate And Netupitant/Palonosetron To Be Presented At Annual BioSpace, 2 weeks ago
Study Findings from Eisai Provide New Insights into Cirrhosis (Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing...
Study Findings from Eisai Provide New Insights into Cirrhosis (Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure) By a News Reporter-Staff News Editor at Clinical Trials Week -- Research ...4 Traders, 4 days ago
EISAI : Patent Application Titled "Ophthalmic Composition Comprising Geranylgeranylacetone" Published Online
By a News Reporter-Staff News Editor at Life Science Weekly -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a patent application by the inventors MIYANO, Takayuki ( Osaka , JP); KUROSE, Takahiro ( Osaka , ...4 Traders, 1 week ago
Studies from Eisai in the Area of Medicinal Chemistry Described (Design, synthesis, and structure-activity relationships of a series of novel...
Studies from Eisai in the Area of Medicinal Chemistry Described (Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists) By ...4 Traders, 1 week ago
on your WebpageAdd Widget >Get your members hooked!